Medindia
Medindia LOGIN REGISTER
Advertisement

Cellectricon Receives Milestone Order for Cellaxess(R)HT, the World's First High Throughput RNAi Screening System

Thursday, November 13, 2008 General News
Advertisement
GOTHENBURG, Sweden, November 12 Cellectricon, a leadingprovider of advanced screening solutions for drug discovery, has todayreceived its most significant and largest single order to date. The orderincludes three Cellaxess(R)HT systems and the customer is a leading USbiotech firm.
Advertisement

"An order of this magnitude proves the system's unique features andvalue, and validates Cellectricon's strategy to bring state-of-the-artproducts for drug discovery and research to the market through world-classcustomer collaborations." says Jonas Ohlsson, CEO at Cellectricon."Cellectricon has developed the Cellaxess(R)HT system in close collaborationwith leading pharmaceutical companies and academic research groups to meetthe rapidly growing demand for a true high throughput transfection screeningtechnology, capable of reagent-free delivery of genetic material tobiologically relevant cell types."
Advertisement

Cellaxess(R)HT is the world's first fully automated workstation for highthroughput RNAi screening on biologically relevant cell types. The systemenables reagent free delivery of siRNA and cDNA to a wide range of primarycells and cell lines with excellent efficiency and viability at a throughputof 50, 000 wells per day. Cellaxess(R)HT is first of its kind on the marketand will significantly impact target discovery by providing key functionaldata in relevant primary human cells.

About Cellectricon

Cellectricon AB, a Swedish biotech company, successfully providesgroundbreaking products to the pharmaceutical and biotechnology market. Thecompany utilizes state-of-the-art interfaces to biological systems byemploying novel microfluidic technologies. Cellectricon's products addresscritical bottlenecks in the drug discovery process and have been adopted bytop-reference customers, including nine of the top ten pharmaceuticalcompanies. In 2007 the company increased its annual revenue by almost 50%. In2008-2009 the company is launching two pioneering large-scale screeningplatforms developed in close collaboration with leaders in the pharmaceuticalindustry. Used in pre-clinical pharmaceutical development, the Cellaxess(R)HTSystem enables high throughput RNAi screening and the Dynaflow(R)HT Systemgreatly advances ion channel drug discovery.Contact Details: Jonas Ohlsson, CEO Phone: +46(0)709-73-47-92 E-mail: [email protected] Susanne Fagerlund VP Marketing & Communications Phone: +46(0)31-760-35-15 E-mail: [email protected]

SOURCE Cellectricon AB
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close